Erkko O. Ylosmaki

Helsinki, 00790, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines.

PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines.

Journal: International journal of biological macromolecules

Published: August 01, 2023

Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses.

Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses.

Journal: Molecular therapy oncolytics

Published: August 31, 2022

Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.

Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.

Journal: Frontiers in immunology

Published: November 30, 2021

PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification.

PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification.

Journal: ACS nano

Published: October 04, 2021

Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.

Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.

Journal: Pharmacology & therapeutics

Published: September 27, 2021

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.

Journal: Journal for immunotherapy of cancer

Published: July 21, 2021

Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin.

Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin.

Journal: Journal for immunotherapy of cancer

Published: June 15, 2021

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.

Journal: eLife

Published: June 11, 2021

A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella.

A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella.

Journal: Molecular therapy oncolytics

Published: June 09, 2021

Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy.

Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy.

Journal: Cancers

Published: June 03, 2021

Viral Nanoparticles: Cancer Vaccines and Immune Modulators.

Viral Nanoparticles: Cancer Vaccines and Immune Modulators.

Journal: Advances in experimental medicine and biology

Published: February 05, 2021

Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.

Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.

Journal: Molecular therapy oncolytics

Published: November 24, 2020

Showing 1-12 of 26

Last Updated: 09/26/2026